canada - search results

If you're not happy with the results, please do another search

0 3508


With the Trump Administration in complete disarray and touting debunked information about Cannabis & Opioid connections we at decided to play a little game of devils advocate. The fact remains that the Trudeau administration remains progressive and is doing what all governments should be doing i.e. listening to its people. Canadians are in overwhelming support of legal cannabis markets which is why they legalized medical marijuana last year. This year the country plans on legalizing recreational use in an effort to crush black markets, create jobs, industry and position itself as a worldwide leader in cultivation. With a completely legal market Canada will face one major issue that will reap major benefits to public cultivation companies. That issue being one of supply and demand. Already operating at a deficit and coupled with an approval process by Health Canada that can take years we foresee investors sending their capital north of the border unless they are invested in companies insulated by restrictions on the recreational markets. Those US companies being: Construction for Cultivation, manufacturers of products, companies monetizing industrial Hemp’s many uses, CBD manufacturers, technology & media services (like us).

One of the highly anticipated events of 2017 is the tabling of legislation as it relates to a legal recreational cannabis program in Canada. This development is expected to take place in the Spring.

During December, a federal task force released its long-awaited recommendations relating to the legalization of recreational marijuana. The report was prepared by a committee comprised of nine members who have worked together since June.

All Eyes on Legislation this Spring

When Canada legalizes recreational marijuana, demand is going to increase significantly, however it will take time for the program to be up and running. For this reason, Canadian licensed medical cannabis producers have been aggressively raising capital to make acquisitions and to increase production capacity.

One of the largest fundamental changes within the Canadian cannabis sector over the last year relates to the amount of capital entering the industry as well as the source of the capital. The capital entering the industry is not only larger but smarter too; these investors and firms are long-term holders that see the bigger picture.

Five Opportunities to Watch

The Canadian cannabis industry has continued to be a bright spot for cannabis investors and 2017 has already provided investors with strong investment returns.

This sub-sector of the cannabis industry has been on fire since July 2016 and the increased interest has been fueled by anticipation of Canada becoming the first G-7 nation to legalize recreational cannabis.

Although the Canadian cannabis industry offers investors a lot of opportunity, it does not come without risk. Many of the companies levered to this sector have seen a significant rally over the last six months while some have not fared as well.

We want highlight five Canadian cannabis stocks that should be on every investors radar. From

The Green Organic Dutchman’s second round of financing closes today at 5pm and investors can still reach out to if they still want to access this opportunity.

Terms of the offering are as follows: The company is selling units at $1.15 CAD per unit and the minimum purchase level is 5,000 units. Each unit consists of one common share and one full share purchase warrant. Each warrant provides the investor to purchase shares of The Green Organic Dutchman at $2.15 for the next two-years no matter what price the shares are trading at.

The Green Organic Dutchman produces farm grown pharmaceutical grade organic cannabis. The company has differentiated itself from the competition by producing high-quality organic cannabis that sells for a higher price and has better profit margins. The company is led by a management team that has a proven track record of success with licensed Canadian medical cannabis producers such as OrganiGram and Emblem Corp.

Aphria (APH.V: TSX Venture) (APHQF: OTC) has been one of the top performers this year and the shares are up approximately 30% YTD. The shares moved considerably higher after the company received conditional approval to up-list on the TSX exchange and we remain favorable on the company’ long-term outlook.

In early February, Aphria announced a $50 million private placement at $5.00 a share and this transaction is expected to close this week. The company expects that 80% of the net proceeds will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated towards strategic investments.

The Part IV expansion will increase Aphria’s capacity from 300,000 to 1 million square feet. In addition, the company’s infrastructure will grow to over 250,000 square feet which is necessary to service the expected 70,000 kilograms of eventual annualized harvests. The project includes 700,000 square feet of Dutch style greenhouses, 230,000 square feet of infrastructure, including new Level 9 vaults, automation for all the greenhouses, processing areas, warehouse facilities, a 15 MW power and heat co-generation facility and security consistent with ACMPR standards.

Aphria anticipates completion of Part IV within 12 months, Health Canada approvals within 4 months of completing the expansion and first harvest within 4 months after such approvals.

In December 2016, Aphria invested $8.4 million in Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF: OTC) at $1.40 a share. Canabo is another stock we are very favorable as the shares trade at an almost 40% discount to the level at which Aphria invested at.

Canabo owns and operates the largest line of medical cannabis clinics in Canada and we expect to see the company continue to expand its footprint across Canada.

CMM.V is trading at $0.85 after the shares rallied more than 13% on above-average volume. We highlighted the company last month as an attractive opportunity and continue to see upside to current levels. The company’s United States symbol, CAMDF is trading below $0.67 after a 16.4% rally and we continue to see upside to these levels.

PharmaCan Capital (MJN: TSX Venture) (PRMCF: OTC) has the top performing licensed Canadian medical cannabis producer this year and the shares are up 92.6% YTD. The company does business as Cronos Group and in 2016, it sold one of its properties to NYSE-traded Innovative Industrial Properties (IIPR).

The shares were under pressure last week after the company announced a $15 million private placement at $2.25 a share. MJN.V quickly bounced back and rallied more than 40% over the few trading days.

The company’s wholly-owned subsidiary, In The Zone, recently received approval from Health Canada to sell medical cannabis. This comes while its other wholly-owned subsidiary, Peace Naturals is positioned to capitalize on the recent medical cannabis legislation in Germany through its export relationship with Pedanios GmbH.

Although the shares have recent run significantly higher, we have become increasingly favorable on the company over the last quarter and continue to monitor trading closely. Become a Technical420 Premium Member to keep up with our analysis.

Canopy Growth Corp. (WEED.TO: TSX) (TWMJF: OTC) continues to be the Canadian medical cannabis leader and we view the company as one of the best long-term cannabis investments.

The company recently completely the acquisition of Mettrum Health, which significant expanded its product line and led to a surge in revenue. The market did not initially respond favorable to Canopy earnings report and the shares recorded its largest drop of the year.

During the quarter, Canopy Growth recorded $3 million in net income off $9.8 million in revenue and total revenue increased 15% when compared to the prior quarter and 180% when compared to the same period last year.

During the quarter, the company sold 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram, up from 462 kilograms at an average price of $7.34 per gram during the prior year period.

The company recorded strong growth on pretty much all metrics and as of December 31st , Canopy Growth reported to have over 29,000 registered patients which is more than 260% higher than the number of patients as of December 31, 2015.

Canopy has recaptured most of its losses and we continue to remain favorable and monitor trading activity closely. WEED.TO recently traded into the $13.20 range and the shares are currently trading at $12.64. We remain favorable on Canopy Growth and this company should be on every cannabis investor radar screen.

0 2942

Vinergy Resources/MJ BioPharma to Acquire 65% of Health Canada and FDA Licensed Laboratory to Pursue Drug Testing and Dosage of CBDs, THC and Terpenes

Biolennia will provide a host of drug testing services to support MJ BioPharma’s product line and provide research and development (R&D), product formulation, extraction facilities, systems design and develop standard-operating-procedures (SOPs). The lab is currently in the process of applying for a Dealer’s License from Health Canada. Once issued the license will allow the Company to process cultivated cannabis (extracts and/or derivatives) for R&D purposes.

Biolennia was founded in 2001 by Dean Swift as the internal R&D and quality testing laboratory to support Micrylium Laboratories Inc. (“Micrylium”). In 2002 it upgraded to a full active ingredient and microbial testing laboratory for several Health Canada approved products. Biolennia is a specialty development laboratory with expertise in Microbiology (bacteria, fungi, viruses), Chemistry (proteins, enzymes, drug testing, material science and analytics). The Laboratory currently provides testing, R&D and quality control for a proprietary line of Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrlylium.

Biolennia has in-house expertise in methods accepted by Health Canada and the Federal Drug Administration (FDA) for determining purity and quality of many of the materials and methods used in validating cannabis and or testing cannabis products. Biolennia brings a highly talented team of Microbiologists who are familiar with testing high purity water, ethanol, ethyl acetate, propylene glycol, xylitol, glycerine, propandiaol, d-limonene, myrcene, and beta caryophelline.

The lab operates from a secure premises in Toronto, Ontario (Canada) alongside Micrylium which manufactures products registered under licensure from various agencies including: CE, FDA, EPA, Health Canada, Swiss BAG, and German VAH. MJ BioPharma will provide the proprietary line of disinfectant products, globally to the cannabis industry to ensure improved hygiene for cultivation facilities, nutrient hoses, labs, extraction systems, dry utensils and edibles manufacturing spaces.

Under the terms of the acquisition Vinergy/MJ BioPharma will acquire 65% of Biolennia for CAD $260,000 and 150,000 shares of Vinergy at the time the definitive agreement is signed. The Company expects to close on the acquisition in Q1-2017.

“This is a fantastic acquisition for us and supports our entire product line and R&D initiatives moving forward. Our technical expertise in drug testing, extractions, and formulas containing CBD, Terpene, THC and other botanicals is continually being furthered. We have a remarkable team. We feel strongly that science based products formulated from extracts and derivatives that are properly dosed and manufactured in GMP environments to ensure consistency and safety for all customers whether they be recreational or medical users, is the future of the cannabis industry,” MJ BioPharma CEO Kent A. Deuters.

European Acquisition Update

Based on early due diligence the Company has terminated its letter of intent announced February 02, 2017 to acquire up to 51% a European plant breeder.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Vinergy Resources Ltd.

0 6779

Canadian licensed medical cannabis producers built off the momentum from Wednesday and benefited from this as it carried into Thursday’s trading session.

These movements are significant because several of these stocks were under pressure on Tuesday and early Wednesday (post-Canopy Growth earnings).

Investors should keep an eye on how this sub-sector continues to trade as we believe it is comprised of some of the highest quality opportunities for investors.

We recapped some of these recent price movements and provided our updated thesis below:

Canopy Growth Corp (WEED.TO: TSX) (TWMJF: OTC) recaptured most of its losses from Tuesday after the shares rallied 3.7% on above-average trading volume. We continue to view Canopy Growth as one of the top long-term cannabis investments due to its leading position in the Canadian medical cannabis market. Canopy Growth recently broke below the $10 level and investor should keep an eye on shares as we continue to see long-term upside to current levels.

OrganiGram Holdings (OGI.V: TSX Venture) (OGRMF: OTC) saw a nice rally yesterday and we will monitor how this continues today. OGI and OGRMF rallied more than 5% and this was a nice change from the recent trend. We will provide updates on any significant price movements today. Stay tuned as we continue to hold cautiously.

Emblem Corp. (EMC.V: TSX Venture) (EMMBF: OTC) continued to rally yesterday and the shares were one of the top performers as they also rallied more than 5%. EMC is trading at $4.17 while EMMBF trades near $3.20. We continue to hold as we are favorable on the long-term outlook. Emblem has a lock up coming up in March and we have started to receive questions about this. Although we expect this to cause a short-term dip, we do not expect it to last long and will keep an eye on any significant price movements leading up to this.

Aurora Cannabis (ACB.V: TSX Venture) (ACBFF: OTC) ended the day up less than 2% and we continue to hold onto the shares. We have contemplated exiting this position and re-entering on weakness, however, we have not decided yet. The reason why we are questioning this holding is due to valuation. When you look at Aurora’s fully-diluted market cap, it is over $1 billion which is significant. We view the risk-reward scenario as balanced here and will keep you updated on how the shares move from here.

Aphria (APH.V: TSX Venture) (APHQF: OTC) edged lower yesterday and this move followed an 18% rally over the last week. APHQF traded as high as $5.15 before ending the day at $4.97 and We continue to see upside to current levels but we may trim the size of our position because of the strength of the recent rally.

CanniMed Therapeutics (CMED.TO: TSX) is trading at $11.95 after the shares edged slightly higher yesterday and we are on the sidelines at current levels. Although we are favorable on the company’s recent execution, the exchange it trades on, and its business model; we are cautious at these levels. We will keep you updated on how the shares trade from here

Cronos Group (MJN.V) recaptured all its losses from Wednesday as the shares rallied approx. 8% yesterday. MJN.V is trading at $2.59 and we are on the sidelines at current levels. We were favorable on MJN after Wednesday’s dip and will monitor how the shares respond today. The company announced a bought deal this week at $2.25 a share and this has caused the shares to trade a little more volatile over the last two trading sessions.

0 3515

Canadian cannabis leader Canopy Growth announced that it closed an approximately $7 million stock offering for the recently formed Canopy Health Innovations.

Canopy Health is partly owned by Canopy Growth and private investors. The company operates as a pure research incubator whose mission is to increase the understanding of cannabis based therapies through research, to drive product innovation and to develop an intellectual property portfolio that can be built into commercial opportunities for Canopy Growth and its subsidiaries.

Plans to Commence Clinical Research Studies

Canopy Health will use the proceeds to establish general operations and begin clinical research into the effectiveness of clinically ready whole plant cannabis drug formulations and dose delivery systems on specific indications. The company will conduct clinical research in partnership with licensed third parties, including Canopy Growth.

Canopy Growth CEO Bruce Linton said his intention with Canopy Health is to build an extension of the business that is dedicated to product specialization. By defining how to apply specific cannabis profiles and delivery systems to certain conditions, Canopy will be able to drive physician acceptance and grow the market at the same time.

Pursuant to agreements between the companies, Canopy Growth will act as a primary supplier of cannabis products for clinical research. It will also act as a research partner through its Tweed Inc. subsidiary which recently acquired a Dealer’s License from Health Canada. This license allows Tweed to possess cannabis and cannabis by-products for the purposes of analytical testing. It also allows the company to use these products for the commercialization of intellectual property by Canopy Health.

Canopy Hires a Founding President and Director

Canopy Growth (CGC.TO) (TWMJF) also announced that Marc Wayne will join Canopy Health as its founding President and Director. Wayne is thought of as a pioneer in the Canadian medical cannabis field having co-founded Bedrocan Canada and serving as its founding Chair.

Wayne played a key role in helping develop the Canadian Consortium for the Investigation of Cannabinoids and turning it into a global innovator in education and research on the medical uses of cannabis. Effective upon the closing of the offering, Wayne resigned from his position as Managing Director of Canopy Growth Corp and as President of Bedrocan Canada Inc.

Completes $60 Million Capital Raise

This morning, Canopy Growth announced that it closed its previously announced $60+ million capital raise at $10.60 a share. The offering was underwritten by a syndicate of underwriters led by GMP Securities L.P. and Dundee Capital Partners, and including Cormark Securities, PI Financial, and Canaccord Genuity .

Canopy Growth intends to use the proceeds for potential real estate acquisitions and fit-up of growing operations at such locations. In the event such potential acquisitions are not completed, a majority of the funds will be used to expand capacity at its existing sites over the next 12 months. Additionally, the company expects to incur international development expenditures of approximately $2,000,000 primarily to further explore and develop international market opportunities where federally legal to do so.

The balance of the net proceeds will be used for general working capital purposes, such as potential acquisitions for both capacity and brand augmentation and related integration, and developing new product offerings. The company may reallocate these funds as market and regulatory indicators warrant in light of the anticipated legalization of a national recreational cannabis market and the ACMPR.

An Emerging Trend

Over the last quarter, we have noticed a trend in the emerging Canadian cannabis industry where licensed producers are significantly increasing their focus on the development of cannabis drug formulations and dose delivery systems for specific ailments and debilitating illnesses.

Earlier this month, Emblem Corp (EMC.V) (EMMBF) commenced trading on the TSX venture exchange after a very successful initial public offering. The company is comprised of three distinct divisions. One of the company’s divisions is Emblem Pharmaceuticals and it is focused on pioneering the next generation of Canadian medical cannabis by providing medication in standard pharmaceutical dosage formats.

Emblem Pharmaceuticals is a very attractive aspect of the business as it offers investors leverage to not only the legal cannabis market but also the cannabis pharmaceutical market.

In the second quarter of 2017, Emblem Pharmaceuticals President John Stewart will lead the launch of cannabinoid-based medications in customary pharmaceutical dosage forms such as liquids, gel caps, oral sprays, and inhalers.

Stewart has over 30 years experience developing and commercializing pharmaceutical products. He has launched 11 new products, including OxyContin, and was the worldwide President and CEO of Purdue Pharma, the largest privately held pharmaceutical company in the world.

Since inception, management has invested over $6 million in the company and executed flawlessly on the business plan to create a production facility that offers premium products. We are very excited about Emblem’s opportunity within the pharmaceutical market of the cannabis industry on account of its best-in-class leadership, its state-of-the-art production facility and its continued execution.

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report


Authored By: Michael Berger

To read more from Michael Berger’s take on Biotech companies read this

0 1119

Arcturus led Canada Division Receives new Purchase Orders and Begins ETL Certification for its Award-winning Cannabis Grow Lights

According to LEDInside: LED Lighting Market to reach US$30.5 Billion in 2016 and Professional Lighting Markets to see explosive growth.

“Our LED business is gaining more traction in the marketplace due to many factors that we suspect are related to the scaling of cultivation centers for both the cannabis and urban farming sectors. On a daily basis, we have seen an increase in inquiries since November 8th , which is exciting given our LED division is vital to cultivation expansion in North America ,” said Mr. William Gildea , Arcturus Growthstar Technologies Inc.’s CEO and Chairman. “This month, the Company shipped its largest single order to a single commercial customer, which operates a chain with 200 locations.  The customer is currently testing the LED lighting in key markets and structuring a rollout to its other locations throughout Canada .”

About Chip On Board (COB):

LEDs compete with traditional lighting sources in a number of ways, including greater energy efficiency, longer lifetime, and smaller size. However, the one drawback that has vexed many lighting designers is cost, which is a key reason why LED manufacturers continue to innovate to improve economies of scale. One of the newest packaging solutions designed to help lower costs is Chip on Board (“COB”) light source modules, in which the LED chips are in the form of a semiconductor chip that is neither encased nor connected but directly mounted onto a PCB or, more generally, a substrate. This packaging style also provides several related benefits, such as greater design flexibility, better light distribution, and simpler manufacturing processes.

Arcturus believes that its Scorpion COB LED Grow lights has the best LED technology to grow legal cannabis on the market and can offer its lights at the best price as compared to its competitors, which gives it a distinct market advantage in the cannabis space.   After Arcturus’ own Rob Huston won 1st place in the Cannabis Cup using the Company’s COB Grow lights, the Company is moving forward with ETL certification (a product bearing the ETL Listed mark is determined to have met the minimum requirements of prescribed product safety standards), after which it will be beefing up sales and marketing efforts throughout Canada and the Unites States.

Arcturus’ LED division reports that the month of November has been the best sales month to date. The Company is also pleased to announce that it is currently testing its COB Grow Lights through an academic study. This project will be a ANOVA of LED horticulture fixtures using IBM-SPSS statistical software.  The Company is looking forward to continuing its momentum in 2017 with the rollout of new LED testing results, plus new sales and marketing initiatives.

“As we move towards a more aggressive sales and marketing push in the Cannabis space for 2017, these independent third party testings are critical to gaining more market acceptance of our LED grow lights,” says Rob Huston , LED Canada’s manager and winner of the Cannabis Cup. “In addition to third party testing, it is expected that the Company will be gaining ETL certification in the next 60 days, opening up the entire North American marketplace, which we believe will have a very positive effect on sales for Arcturus’ COB Grow Lights and LED Canada’s sales in 2017.”

For further information, contact William Gildea , Director, at 617.834.9467.

On behalf of the Board,
Arcturus Growthstar Technologies Inc.
William Gildea , CEO & Chairman

About Arcturus

The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Arcturus provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

0 1165

Through an amazing act of unity, the leaders of the three major parties in Ontario stand together to demand some sort of direction from the Trudeau government on its hazy plans towards legalizing marijuana. Despite the gestures of announcing legislation by spring of 2017, establishing a task force, and building an online opening for Canadians to share their views, the ultimate framework for cannabis regulation remains unclear.

Ontario Liberal Premier Kathleen Wynne, Progressive Conservative Leader Patrick Brown, and NDP Leader Andrea Horwath join forces during a session at Queen’s Park to get some clarity on where things stand in the process of legalizing marijuana. Ontario so far has been a war zone between the cannabis community and law enforcement. This is largely because of the rapid growth and development of marijuana dispensaries across Toronto and other parts of the province. Because of a lack of direction from the federal government, Ontario legislators have simply made the decision that there is no legal vacuum for dispensaries to operate.

A complete opposite and more progressive outlook is coming from provinces like British Columbia, where officials have learned to work with dispensaries by establishing zoning bylaws that permit them to exist under a set of rules. This move has been deemed by the cannabis community and reemphasized by the media as a much more collaborative approach than actions like Project Claudia, one of the largest police raids in Canadian history.

Claudia’s show of unnecessary restraint has been widely considered by citizens and government officials as a huge waste of public money that did very little to stop dispensaries, which simply reopened for business the following week. This appeal to the federal government on behalf of the leaders of Ontario comes on the heels of the Ontario Chamber of Commerce publicly asking Premier Wynne to permit recreational marijuana to be sold by private retailers licensed and authorized by the government.

Opponents of marijuana legalization are criticizing the government for taking their time, adding that this slow process is allowing for a “Wild West” style scenario, where businesses can seemingly operate with no regulation. Those who stand for legalizing marijuana, on the other hand, want the feds to speed things up in order for cannabis businesses to know how to operate once they learn the rules.

0 1265

Canada will press the United States to change an outskirt approach that has banished Canadians who confess to having utilized weed from making a trip to the United States, given that Canada arrangements to authorize pot, an administration representative told Reuters on Friday. The instance of a Canadian man banned from U.S. traveling on the grounds that he confessed to having smoked pot recreationally has blended open deliberation over United States fringe specialists invoking a government law against weed use, despite the fact that pot use is legitimate in a few states and forthcoming lawful in Canada.

English Columbia inhabitant Matthew Harvey was halted at a United States fringe crossing in Washington state in 2014 and got some information about recreational pot use. Whenever Harvey, 37 at the time and who had a license to utilize medicinal weed, said he had smoked pot recreationally, he was confined and addressed for six hours before being denied section and banished from future passage.

“They said that I was inadmissible because I admitted to smoking marijuana after the age of 18 and before I’d received my medical marijuana license,” said Harvey.

In a meeting with the CBC, Canadian Public Safety Minister Ralph Goodale said that the circumstance should have been tended to, especially in light of uneven weed confinements in the United States.

“We obviously need to intensify our discussions with our border authorities in the United States, including the Department of Homeland Security,” Goodale stated. “This does seem to be a ludicrous situation. Three or four other jurisdictions in the United States. [T]here’s certain ironies about the current American position that we will certainly be very vociferous in putting before them.”

Four U.S. states — Washington, Colorado, Alaska, and Oregon — have sanctioned recreational cannabis use, as has the District of Colombia. Additionally, 25 states have authorized medicinal pot, no less than five of which will settle on recreational pot legalization in November decisions.

0 1199

Although the United States cannabis industry offers investors a lot of upside, it offers even more risk as a majority of the companies are fraudulent. Many of the cannabis companies that trade on the OTC exchange are led by management teams focused on creating value for themselves, and rely on the sale of stock to stay in business. Canada Remains a Bright Spot of the Industry

The Canadian medical cannabis industry continues to be a bright spot in the cannabis sector as its constituents are led by management teams that continue to execute on business initiatives and create value for shareholders. One the biggest developments in 2015 was the victory by Justin Trudeau and the Liberal Party in the Canadian general election.

The outcome of the campaign was a huge victory for the Canadian cannabis industry and will serve as a catalyst for stocks levered to this industry. Justin Trudeau and the Liberal Party have said they will make cannabis legalization a priority.

A Growing Program

In 2014, Canada created a federal medical cannabis program called Marihuana for Medical Purposes Regulations (MMPR). The program has enabled the country to move from a system that allowed patients to buy from a single government‐approved grower or to either grow their own or purchase from non‐commercial growers, to a system of multiple commercial providers. The Canadian medical cannabis industry is growing at an impressive 10% per month and it now has more than 75,000 patients. There are currently 31 federally licensed medical cannabis producers in Canada under Health Canada’s MMPR.

Catalysts Ahead

Canada has announced plans to legalize recreational cannabis in spring 2017. Before recreational cannabis is legalized, we expect to see consolidation within the industry.

The government’s plan to legalize cannabis has made several licensed medical cannabis producers attractive investment opportunities to institutional investors, hedge funds, and investments, banks. Licensed medical cannabis producers have raised more than $50 million so far this year and we expect this number to increase exponentially during the back half of the year.

This has made capital much easier to access, which has supported growth initiatives like land acquisitions, construction costs, license/company acquisitions, production capacity increases, etc. The number of investments like this have increased significantly this year as licensed producers prepare for an extended period of accelerated growth following these various event-driven catalysts.

Authored By: Michael Berger

0 1130

Canadian medicinal cannabis users can cultivate their own marijuana or motivate somebody to make it for them under new, extended laws that happen in the not so distant future; Health Canada announced Thursday. Patients affirmed for therapeutic weed will be capable of registering with Health Canada to grow a restricted measure of cannabis for their own medicinal purposes.

“If an individual wants to produce a limited amount of cannabis for his/her own medical purposes, he/she must submit an application to register with Health Canada,” a department background document stated. “An original medical document from the health-care practitioner must be provided, and the application must include information such as the location of where cannabis will be produced and stored.”

They are also able to assign another person to develop it for them. For instance, if they’re not sufficiently healthy enough to grow their own, the other individual passes a record verification demonstrating that they haven’t been sentenced a medication offense in the last decade and aren’t developing for more than two people, themselves included. The third alternative is getting it from one of 34 Health Canada-affirmed makers — the primary legitimate source under the present laws. Wellbeing Canada authorities said in a specialized preparation Thursday evening this constrained sum of individuals can develop at their home will be connected to the day by day measure of cannabis a patient is recommended.

For example, somebody recommended a gram a day could grow two plants outside or five plants inside to have the capacity to supply themselves, Health Canada said, since plants developed outside yield more supply than indoor plants. The seeds and plants would originate from these authorized makers, who could offer an interval supply of cannabis to individuals as they sit tight for their homegrown supply to be prepared. The new guidelines take effect on Aug. 24.

0 823

Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)

Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (“Abattis”) is pleased to announce that it has received a Natural Product Number (“NPN”) approval for Phyto(NOS)™. This NPN allows Abattis to manufacture and to sell Phyto(NOS)™ in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)™ in the United States.

Phyto(NOS)™ is an all-natural, patent-pending formulation that naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants that help protect against oxidative cell damage caused by free radicals. Phyto(NOS)™ has applications in a wide range of food, beverage and nutraceutical products.

Abattis Director and product designer, Brazos Minshew, says “I designed Phyto(NOS)™ to deliver bio-active Nitric Oxide to the body in a natural, sustainable and metabolically-friendly manner. Nitrates in the plant-based ingredients of PHYTO[NOS]™ get converted quickly into nitric oxide. This action is faster and doesn’t require enzymes. The benefits are seen with very small quantities of nitrates under conditions of both high and low oxygen.”He adds, “In our NÖXX Botanical Blends line of products, PHYTO[NOS]™ is blended with other natural fruit and herb extracts to target specific health concerns by enhancing the benefits and focusing the desired effects in each of our products.”

Our market research and outreach within our target markets validates both the need and the demand for the NÖXX Botanical Blends line of products. Early interest from customers and other product developers interested in all-natural nitric oxide support has been very positive. The worldwide market for products where nitric oxide is involved in the mechanism of action is expected to reach US$147 billion in 2019.(1)

The discovery of the nitric oxide pathway is recognized as a critical advancement in cell signaling and has led to major advancements in many clinical areas that have the ability to transform biotechnology and medicine. Important therapeutic areas for nitric oxide-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. Decreased production and or bioavailability of nitric oxide is recognized as being one of the earliest events in the onset and progression of many diseases.(2)


“Rene David”
Rene David, CFO

For further information, contact the Company at (604) 336-0881 or



This press release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “interest,” “may,” “will,” “project,” “should,” “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on While the Company may elect to, it does not undertake to update this information at any particular time.

(1) Jain PharmaBiotech. Nitric Oxide: Therapeutics, Markets and Companies. Press Release (2010)
(2) Nathan S Bryan, Nitric oxide enhancement strategies. Future Science OA. August 2015, Vol. 1, NO.1

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements